MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA

淋巴瘤患者的骨髓移植

• 批准号: 3805845
• 负责人: FREDERICK APPLEBAUM
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3805845
• 关键词: Burkitt's lymphoma; Hodgkin's disease; autologous transplantation; bone marrow transplantation; carmustine; clinical trials; combination cancer therapy; combination chemotherapy; cyclophosphamide; drug adverse effect; graft versus host disease; hematopoietic tissue transplantation; histocompatibility; histocompatibility typing; homologous transplantation; human subject; lymphoma; major histocompatibility complex; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer remission /regression; pneumonia; radiation immunosuppression

The use of high dose chemoradiotherapy followed by marrow transplantation can cure some patients of malignant lymphoma after they have failed conventional chemotherapy. In this project we propose to determine more precisely the curability of patients transplanted for malignant lymphoma at first relapse or second remission. We will investigate the influence of disease histology and allogeneic marrow on treatment outcome. Patients with a prior history of radiotherapy to the chest are at high risk to develop interstitial pneumonitis after our standard CY-TBI regimen, and for this group we propose to test a chemotherapy- only preparative regimen. Other new preparative regimens (as outlined in sections I.A. and I.B.) will be tested in patients transplanted for refractory disease. Finally, we will compare prospectively marrow transplantation to the best available salvage chemotherapy in patients who have relapsed after first line chemotherapy.

使用大剂量放化疗后骨髓 移植可以治愈一些恶性淋巴瘤患者 在常规化疗失败后。 在这个项目中 我们建议更精确地确定患者的治愈能力， 恶性淋巴瘤首次复发或第二次复发时移植 缓解。 我们将研究疾病组织学的影响 和同种异体骨髓对治疗结果的影响。 患者 既往胸部放疗史的患者， 在我们的标准CY-TBI后发生间质性肺炎 方案，并为这一组，我们建议测试化疗- 只有准备方案。 其他新的制备方案（如 概述见第一. A节。和I. B.）将在病人身上进行测试 移植治疗难治性疾病 最后，我们将比较 前瞻性骨髓移植， 首次化疗后复发的患者的挽救性化疗 线化疗。